How does FDA decide which supplement facilities to inspect?

FDA selects facilities for inspection based on several factors: routine scheduling (all registered facilities should expect periodic inspections), adverse event reports, consumer complaints, import alerts, surveillance of the marketplace, and risk-based prioritization. New registrations, facilities that have never been inspected, and those with prior violations receive higher priority. FDA does not announce inspections in advance for domestic facilities.

What is a Form 483 observation?

A Form 483 is a document FDA inspectors issue at the end of an inspection to list conditions or practices that may violate FDA regulations. Each observation describes a specific deficiency found during the inspection. Receiving a 483 is not a final determination of violation. FDA encourages companies to respond in writing within 15 business days (this is a recommended timeline, not a statutory requirement). If the FDA receives a response within that window, it will generally review the response before deciding whether to issue a warning letter. Failure to correct 483 observations can lead to warning letters, injunctions, or consent decrees.

Is the brand owner responsible if the contract manufacturer fails an FDA inspection?

The brand owner is responsible for ensuring their products are manufactured in compliance with 21 CFR Part 111. If your contract manufacturer fails an inspection and the violations affect your products, FDA may take action against both the manufacturer and your brand. This is why quality agreements, regular audits of your manufacturer, and maintaining your own documentation are critical. Brand owners should review their manufacturer's most recent inspection history and 483 response before production begins.

Preparing for an FDA Inspection: What Supplement Brand Owners Should Know

FDA inspections are not a matter of if, but when. Every registered supplement manufacturing facility will eventually be inspected. As a brand owner, you may not control the facility, but you are responsible for ensuring your products meet federal standards. Understanding what inspectors look for helps you choose better manufacturers and protect your brand. Your regulatory attorney should be involved in preparing for any inspection that affects your products.

Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.

How FDA Selects Facilities for Inspection

FDA inspections of domestic supplement facilities are unannounced. Inspectors arrive and present credentials. The facility cannot refuse entry (though they can request a brief delay to contact management).

FDA prioritizes facilities based on several factors:

Risk-based scheduling: facilities producing higher-risk products or those that have never been inspected receive higher priority.
Adverse event reports: a cluster of reports associated with a specific product or facility can trigger an inspection.
Consumer complaints: reports submitted through MedWatch or other channels.
Prior inspection history: facilities with unresolved 483 observations or warning letters are inspected more frequently.
Import alerts: products flagged at the border may trigger a facility inspection.

The enforcement environment has intensified. Industry observers note that merely having a cGMP registration is no longer adequate. FDA expects active, documented compliance programs.

What Inspectors Review

Inspectors evaluate compliance with 21 CFR Part 111 across six major areas:

Personnel

Training records, qualified supervisors, hygiene practices, documented responsibilities. Inspectors verify that everyone involved in manufacturing has documented training on their specific duties.

Plant and Grounds

Facility cleanliness, pest control, water supply, sewage, lighting, ventilation. Physical separation between raw materials, work-in-progress, and finished products.

Equipment

Calibration records, cleaning procedures, maintenance logs. Equipment must be appropriate for its intended use and maintained in a clean and orderly condition.

Production and Process Controls

Master manufacturing records, batch production records, in-process controls. Inspectors verify that written procedures exist and are followed for every production step.

Laboratory Operations

Testing methods, instrument calibration, reference standards, written procedures. Lab results must be traceable to specific batches and methods.

Records and Record-Keeping

Batch records, complaint files, adverse event logs, testing records. Records must be accurate, complete, and retained for the required periods.

Form 483 Observations Explained

At the end of an inspection, the inspector presents a Form 483 listing any conditions or practices that appear to violate FDA regulations. A 483 is not a final finding. It is an opportunity to correct problems before FDA takes formal action.

Common 483 observations for supplement facilities include:

Failure to establish and follow written procedures for production and process controls
Inadequate identity testing of incoming ingredients
Incomplete or missing batch production records
Failure to verify that finished products meet specifications before release
Inadequate cleaning and sanitation procedures for equipment
Missing or incomplete training documentation for personnel

The facility should respond in writing within 15 business days. The response should describe corrective actions taken or planned, with specific timelines. A strong, detailed response can prevent escalation to a warning letter.

When a 483 Becomes a Warning Letter

If a facility does not adequately address 483 observations, FDA may issue a warning letter. Warning letters are public documents. They appear on the FDA website and in industry databases. Retailers and other business partners routinely check for them.

Warning letters can lead to more severe consequences: injunctions (court orders to stop production), consent decrees (legally binding agreements to change practices), product seizures, or criminal prosecution in extreme cases.

For more on warning letters and enforcement outcomes, see our compliance risks guide.

Brand Owner's Role vs Manufacturer's Role

Your contract manufacturer operates the facility. They manage personnel, equipment, and production. But as the brand owner, you share responsibility for the quality and safety of your products.

Manufacturer's Responsibility	Brand Owner's Responsibility
Maintaining cGMP-compliant facility	Verifying cGMP compliance before contracting
Performing required testing	Reviewing COAs and requesting third-party verification
Keeping batch production records	Requesting and retaining copies of batch records
Training production personnel	Including training requirements in quality agreement
Responding to FDA 483 observations	Requesting copies of 483s and manufacturer responses
Maintaining facility for inspections	Conducting or commissioning periodic audits of the facility

Your quality agreement should specify which documentation you receive, how quickly you are notified of inspection results, and what happens if the manufacturer receives a warning letter.

See our quality agreements guide and manufacturer evaluation framework.

Disclaimer: This guide is an educational overview, not legal or regulatory advice. FDA inspection procedures and enforcement practices are complex and subject to change. Your regulatory attorney should prepare you and your manufacturer for any inspection that affects your products. See our Terms of Service for details.